Subscribe

Articles

An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Paula Anastasia, MN, RN, AOCN; Ali McBride, PharmD, MS, BCPS
Interview with the Innovators, Video
Videos
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics. Read More ›
Meaningful Response Possible with Third-Line Targeted Therapy Rechallenge for Patients with BRAF-Mutation–Positive Advanced Melanoma
Melanoma
Web Exclusives
BRAF/MEK-targeted therapy rechallenge in patients with BRAF-mutation–positive advanced melanoma whose disease progress on first-line BRAF-targeted therapy and second-line immunotherapy leads to responses in approximately one-fourth of patients. Read More ›
Immune-Related Adverse Events Occurring After 2 Years of Anti–PD-1 Therapy Are Common
Melanoma
Web Exclusives
In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment. Read More ›

Page 117 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.